{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:25:47Z","timestamp":1788881147868,"version":"build-2803163510"},"reference-count":0,"publisher":"Medinews (Cardiology), Ltd.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cardiol"],"published-print":{"date-parts":[[2023]]},"DOI":"10.5837\/bjc.2023.002","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:12:48Z","timestamp":1674036768000},"source":"Crossref","is-referenced-by-count":2,"title":["Evaluating initiation and real-world tolerability of dapagliflozin for the management of HFrEF"],"prefix":"10.5837","member":"3870","published-online":{"date-parts":[[2023]]},"container-title":["British Journal of Cardiology"],"original-title":[],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T10:12:49Z","timestamp":1674036769000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjcardio.co.uk\/2023\/01\/evaluating-initiation-and-real-world-tolerability-of-dapagliflozin-for-the-management-of-hfref\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":0,"URL":"https:\/\/doi.org\/10.5837\/bjc.2023.002","relation":{},"ISSN":["0969-6113"],"issn-type":[{"value":"0969-6113","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}